Depression, anxiety, trauma and the treatments and services around them.
Jury selection opened in Los Angeles in a consolidated trial brought by two teenagers against Meta and Snap, the second bellwether since a March verdict found Meta and YouTube liable and awarded $6 million.
The FDA has cleared Wave Neuroscience's MeRT System, which uses a patient's EEG to personalize magnetic stimulation, as an adjunct PTSD treatment. The sham-controlled trial behind it is not yet published.
In 564 German patients with major depression, models built on MRI, genetics, blood and gut microbiome data predicted two-year relapse no better than a few clinical risk factors, reaching at most 64% balanced accuracy.
Rapport Therapeutics says RAP-219 beat placebo by 3.1 points on the Young Mania Rating Scale at three weeks in a 253-patient phase 2 trial, with no serious adverse events but more dropouts for side effects.
Nine caring letters mailed over a year to 87,926 veterans who contacted the Veterans Crisis Line were not associated with lower suicide mortality at 12 months, a JAMA Psychiatry analysis of 227,502 veterans found.
In 277,489 UK Biobank adults, men who were both lonely and socially isolated had about 5.8 fewer years free of depression and anxiety from age 50, and women about 3.7 fewer, a Tulane-led study found.
In a Danish cohort of 2,459 adults with type 2 diabetes, 2.9% screened positive for binge eating disorder symptoms and 3.1% had subclinical symptoms, with higher rates among women and people with severe obesity.
In 187,341 US adults aged 50 and over, an ADHD diagnosis was tied to a more than fourfold higher risk of mild cognitive impairment or dementia, and genetic risk for ADHD showed a smaller but similar link.
A new WHO guide published for World Mental Health Day urges countries to move people out of long-term psychiatric hospital care; only 9% of reporting countries have fully shifted to community-based services.
The FDA has granted 510(k) clearance to Motivista, a prescription smartphone app for negative symptoms of schizophrenia, after a 457-patient phase 3 trial showed a small-to-moderate benefit over a control app.
